# Stem cells weekly evidence review - October 26, 2026

Decision: substantive public article update warranted. New clinical and reporting evidence plus a newly captured official consumer warning. Preserve the original report; no cure claims, dosing, clinic endorsement or travel recommendation.

Access date: 2026-10-26 PDT, verified with system clock. Previous review: October 19. Core literature entry-date and trial-update window: October 20-26 inclusive. Older findings captured now are explicitly dated as catch-up, not described as new discoveries. Targeted weekly monitoring, not a systematic review or exhaustive global approval audit.

Article: https://managingexpectations.net/blog/articles/stem-cells-evidence-costs-risks-global-guide.html
Previous note: https://managingexpectations.net/research/health/stem-cells-weekly-update-2026-10-19.md

## Selected evidence and article edits

### 1. Prevention of a transplant complication: promising randomized phase II evidence

Huan Hua et al. "Short-Course Ruxolitinib Initiated at Neutrophil Engraftment for Prevention of Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter, Randomized, Open-Label, Controlled Phase II Trial." Transplantation and Cellular Therapy. Electronic publication October 24, 2026. DOI: 10.1016/j.jtct.2026.10.031. PMID 42926045.
https://pubmed.ncbi.nlm.nih.gov/42926045/

Primary evidence: NCBI EFetch XML abstract, bibliographic metadata and trial identification checked. Web-page extraction failed; the official XML succeeded. This is abstract-level appraisal, not a full adverse-event-table audit.

At five North China centres, 171 patients aged 12-66 with hematologic malignancies or severe aplastic anemia were randomized to ruxolitinib plus standard prophylaxis or standard prophylaxis alone. The report describes 100-day grade II-IV acute graft-versus-host disease incidence of 14.0% versus 34.1% (subdistribution hazard ratio 0.35, 95% CI 0.18-0.68; P=0.002). Two-year overall survival did not differ significantly (81.4% versus 82.4%; P=0.674). Grade 3 or worse adverse events within 100 days were described as similar, which is not proof of no risk. Pre-transplant measurable residual disease differed between arms and complicates survival interpretation. Open-label phase II design; larger confirmatory trials remain necessary.

Key passage: "MRD-stratified phase III trials are warranted."

Evidence label: promising/under study for this prevention strategy. Ruxolitinib is a medicine used around transplantation, not a new stem-cell product. This report does not establish a new FDA/Health Canada approval, a general immune-reset cure, a survival advantage or a reason to alter treatment. Do not publish administration schedules or doses from the abstract.

Suggested edit: brief dated paragraph focused on reduced acute GVHD, unchanged survival comparison and evidence limits.

### 2. Recovery support: the treatment is more than the cells

Lynn Leppla et al. "Evaluating the effectiveness of the eHealth-faciLitated SMILe-integrated care model on treatment burden, quality of life and graft-versus-host disease after allogeneic stem cell transplantation: results of two European randomized controlled implementation studies." Annals of Hematology. October 24, 2026. DOI: 10.1007/s00277-026-07333-1. PMID 42928398.
https://pubmed.ncbi.nlm.nih.gov/42928398/
https://link.springer.com/article/10.1007/s00277-026-07333-1

NCBI abstract and publisher full text retrieved. Two linked, non-blinded randomized studies in Germany and Switzerland; this paper analyses secondary outcomes for 152 patients, split equally between usual care and an eHealth plus advanced-practice-nurse support model. Treatment burden was lower in five measured dimensions. Acute grade II-IV GVHD incidence was 34.2% versus 55.3% (HR 0.54, 95% CI 0.33-0.88), but health-related quality of life and chronic GVHD did not differ significantly. Authors describe the secondary analysis as exploratory; clinical pathways for the acute-GVHD finding remain uncertain. The support model is multicomponent: do not attribute the result to an app alone or describe it as proof that nursing prevents GVHD.

Key passage: "The acute GvHD finding warrants further investigation".

Evidence label: randomized-study secondary analysis; promising supportive-care evidence, not a new cell therapy. Authors declare no competing interests. Suggested edit: foreground recovery support and treatment burden, with unchanged quality-of-life/chronic-GVHD results. Avoid reproducing all clinical percentages in the public summary.

### 3. Orthopedic evidence: new reporting standards, not approval of injections

Jordy Schol, Luca Ambrosio and colleagues / VERTEBRA Working Group. "The ISSLS VERTEBRA initiative: establishing reporting standards for regenerative medicine trials in disc degeneration and low back pain." European Spine Journal. October 20, 2026. DOI: 10.1007/s00586-026-10373-w. PMID 42900386.
https://pubmed.ncbi.nlm.nih.gov/42900386/
https://link.springer.com/article/10.1007/s00586-026-10373-w

NCBI XML and publisher full text retrieved. International Society for the Study of the Lumbar Spine (ISSLS)-associated consensus process produced a 50-item checklist. Across 36 eligible intradiscal regenerative-medicine trials, mean reporting completeness was 53.8%. Missing details included product characterization, trial methods, imaging, baseline measures and missing-data handling.

Crucial distinction: the score measures reporting completeness, NOT treatment success, efficacy, safety or a direct rating of methodological quality. The full text explicitly distinguishes a reporting framework from an appraisal tool. These trials span intradiscal biologics; do not relabel them all as stem-cell trials. Patents/consulting interests were disclosed for some authors, including Daisuke Sakai; full working-group disclosures are in supplementary material.

Evidence label: professional reporting guidance/evidence-transparency analysis, not a clinical efficacy result. Suggested edit: explain why a published report or positive headline is not enough to judge an injection. No change to the orthopedic efficacy category.

### 4. Official consumer warning, catch-up from October 19

North Dakota Attorney General, "Attorney General Drew Wrigley Warns About Stem Cell Offers," October 19, 2026.
https://attorneygeneral.nd.gov/attorney-general-drew-wrigley-warns-about-stem-cell-offers/

Web extraction timed out; direct official-page retrieval succeeded (HTTP 200), saved locally. The office warned about restaurant/free-dinner sales presentations and unsupported broad treatment claims. It distinguishes FDA-registered facilities from FDA approval of the advertised treatment and warns about physical and financial harm. This is an official advisory, not a new nationwide ban or a court judgment. The report does not repeat allegations against a named company or identify patients.

Key passage: "this does not mean that they have FDA approval for the marketed treatments".

Evidence label: official consumer-protection warning; claims about individual businesses remain attributed to the issuing office. Suggested edit: add the warning as a dated catch-up and reinforce the registration-versus-approval distinction. The advisory's offer-price range is not a market average and is not used to revise the report's pricing section.

### 5. EU clarification: GMP responsibilities, not a new approval

EMA, "Highlights 1st EMA-ISCT bilateral meeting," document EMA/223656/2026, dated October 23, 2026, section 3.2, page 2.
https://www.ema.europa.eu/en/documents/minutes/highlights-first-european-medicines-agency-ema-international-society-cell-gene-therapy-isct-bilateral-meeting_en.pdf
Meeting page (meeting occurred October 5, not October 23):
https://www.ema.europa.eu/en/events/first-european-medicines-agency-ema-international-society-cell-gene-therapy-isct-bilateral-meeting

Official two-page PDF downloaded and extracted. EMA clarified that good manufacturing practice requirements apply when manufacture of an ATMP active substance or finished medicinal product begins; donation/procurement/testing can fall under tissue/cell or SoHO frameworks as applicable. Intended use and processing matter in borderline cases. This is a clarification recorded in meeting highlights, not an enacted new law or a new product authorization.

Key passage: "Borderline cases also require consideration of the cells' intended use and the nature of the processing."

Suggested edit: short clarification with source link in the Europe regulatory row. Keep October 15 Yartemlea negative-opinion wording intact; the medicine page still describes an opinion, not a newly verified European Commission decision.
https://www.ema.europa.eu/en/medicines/human/EPAR/yartemlea

## Required source checks and unchanged conclusions

### FDA

- Approved cellular/gene therapy list: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products
- Consumer page: https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies
- 2026 safety index: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/2026-safety-and-availability-communications

Direct list/index requests returned short 404 responses; alternate web extraction recovered substantive official content, including list entries for Tregzi, Ryoncil and other narrow-indication products. The safety index contains October 22 blood-donation/Ebola information and October 23 BabyBIG information, not a newly verified general stem-cell warning. The consumer page remains dated June 3, 2021. Its historical claim that approved stem-cell products are only cord-blood products must not be used as a current inventory. Registration/trial listing is not approval; current approvals must be checked product by product. No new weekly stem-cell authorization established in this screen.

Broadened search after an empty initial result surfaced FDA's October 6 Tides Medical/APLICOR 3D device warning. Search-lead only in this run; not independently opened or selected as a new weekly action. Do not infer a clinic ban from it.

### Health Canada

- Autologous policy: https://www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/applications-submissions/guidance-documents/cell-therapy-policy.html
- Unauthorized-cell-therapy advisory: https://recalls-rappels.canada.ca/en/alert-recall/health-canada-advising-canadians-about-potential-health-risks-associated-unauthorized
- October 15 quarterly approvals backgrounder: https://www.canada.ca/en/health-canada/news/2026/10/drugs-and-medical-devices-authorized-july-1-to-september-30-2026.html

Policy retrieved directly; advisory and quarterly backgrounder opened through extraction. The advisory's starting date is May 15, 2019, not the extractor's later metadata date. Its historic product count is not a current inventory. No new relevant Canadian cell-therapy rule or general authorization verified. The quarterly list is an approvals summary, not a new weekly stem-cell policy. Autologous origin does not establish exemption or safety.

### NIH/NCI and ClinicalTrials.gov

- NCI: https://www.cancer.gov/about-cancer/treatment/types/stem-cell-transplant
- Registry API: https://clinicaltrials.gov/api/v2/studies
- OpRegen: https://clinicaltrials.gov/study/NCT02286089
- MSCs for COVID-19 ARDS: https://clinicaltrials.gov/study/NCT04345601

NCI directly retrieved; specialist transplant context unchanged. Official registry API query screened stem cell/mesenchymal/iPSC/exosome records last updated October 20-26. Retrieved all pages: 205 records, 205 unique NCT identifiers. Broad search includes non-cell drugs and eligibility mentions; it is not 205 new stem-cell trials. OpRegen's October 23 update does not mean new results were first published then: results first posted March 6, 2023. Likewise the ARDS trial's October 21 update retains results first posted April 1, 2024. No efficacy upgrade based solely on updated timestamps. Raw records remain local because they include protocol/dose information.

### ISSCR and professional orthopedic guidance

- https://www.isscr.org/guidelines
- https://www.isscr.org/isscr-news
- https://www.isscr.org/public-policy
- https://www.orthoinfo.org/treatment/use-of-stem-cells-in-orthopaedics

Direct retrieval succeeded. The obsolete /stem-cell-policy URL returned 404; the correct /public-policy page was found and retrieved. Guidelines still identify August 2025 version 1.2, with targeted embryo-model revisions. Policy emphasizes independent oversight and prevention of unproven-treatment marketing. Alternate news extraction includes the October 20-22 Kyoto iPSC symposium and a future meeting announcement; direct news output was older. A meeting or manufacturing directory is not evidence of human treatment success. AAOS continues to describe insufficient/mixed clinical evidence for orthopedic stem-cell claims. The newly selected ISSLS VERTEBRA paper is about reporting quality, not endorsement of intradiscal therapies.

### Global regulatory and clinic-market checks

- EU: EMA news index https://www.ema.europa.eu/en/news retrieved; it displays a warning that search results may be incomplete. Targeted search found the October 23 meeting-highlights PDF above, independently downloaded. Yartemlea opinion page rechecked.
- UK: https://www.gov.uk/guidance/advanced-therapy-medicinal-products-regulation-and-licensing-in-uk retrieved directly; last update September 11. https://www.gov.uk/government/news/mhra-2030-strategy-to-modernise-patient-centred-regulation-for-the-era-of-ai-and-personalised-medicines opened; dated October 14, it describes strategic commitments, not a new stem-cell approval or enacted blanket exemption.
- Japan: https://www.pmda.go.jp/english/review-services/reviews/approved-information/0004.html retrieved directly. Selective translated index retains March AMCHEPRY/RiHEART entries; not a complete real-time regulatory audit. Broader search found October 15 Stemirac committee-recommendation reporting (https://pj.jiho.jp/article/256617); primary ministry confirmation was not obtained, so no full-approval claim is published. Separately, Osaka KEISATSU Hospital confirms a September 29 insured iPSC-heart-patch procedure: https://oim.or.jp/news/20260929/ (official hospital page, Japanese and English, opened). This is an implementation milestone already before this week's window, not proof of durable clinical benefit. An October 21 patient-testimony lead was not independently authenticated and is not added.
- Singapore: https://www.hsa.gov.sg/ctgtp/overview/regulatory-overview/ direct request 403; alternate extraction recovered framework with an October 16 update date. A timestamp alone does not establish a substantive policy change. Class 1/Class 2 distinction remains. https://www.hsa.gov.sg/ctgtp/class2/summary-of-benefit-risk-assessment-reports/fucaso-suspension-for-infusion/ opened: report published October 5, product approval dated June 18, 2026. Do not turn report publication into a new October authorization.
- Australia: https://www.tga.gov.au/news/news-articles/stem-cell-treatments-and-regulation-quick-guide-consumers direct timeout; alternate extraction recovered historic consumer guidance. Not used as a comprehensive current approval inventory. Broadened search after irrelevant results surfaced an October 13 commercial manufacturing/testing partnership, not a new clinical authorization. No new relevant TGA action verified.
- Mexico/Panama/Cayman: searches produced clinic promotion, social content and older infection reporting, not a verified new regulator action or comparable pricing change. A newly indexed Panama-linked Achilles case is described below; it does not establish clinic efficacy. Sparse search coverage is not certification that nothing happened locally. No clinic endorsed.

## Literature breadth and non-selected leads

PubMed ESearch/EFetch query: (stem cell OR mesenchymal OR iPSC OR exosome OR hematopoietic transplantation) AND (trial OR safety OR adverse OR Parkinson OR diabetes OR spinal cord OR arthritis OR autoimmune OR cancer) AND (2026/10/20:2026/10/26[EDAT]). Returned 446 records; all identifiers and abstracts retrieved. Title/abstract triage and selected full-text checks only, not full appraisal of every paper. Entry date is not publication date. The saved selected bibliography uses article-level DOI fields; broad raw extraction also contains reference DOIs and must not be mistaken for a single paper's identifier list.

- PMID 42897668, DOI 10.1186/s13287-026-05148-5: STEMS progressive-MS long-term follow-up. Newly indexed in this screen but electronic publication July 22. Eleven of twelve patients had long-term data, median 5.7 years. Authors report no serious adverse events attributed to transplantation, but disability progressed; cognition/imaging signals remain exploratory without a proper internal control. Small numbers cannot establish rare-event safety. No MS-cure claim added. https://pubmed.ncbi.nlm.nih.gov/42897668/
- PMID 42899203, DOI 10.7759/cureus.118122, October 18: one Achilles-rupture case with combined MSC/extracellular-vesicle intervention plus rehabilitation. Imaging and function reportedly improved; no comparator and multiple interventions prevent causal attribution. Authors disclose employment at Auragens, the Panama treating institution and product manufacturer. Evidence label: case report, not proof or clinic endorsement. No protocol details published. https://pubmed.ncbi.nlm.nih.gov/42899203/
- Exosome/MSC, diabetes, spinal-cord, arthritis and cancer matches include cell/animal studies, reviews and unrelated oncology drugs. Laboratory mechanisms are not human cures. No broad efficacy-category upgrade justified.
- October MS conference CAR-T press releases surfaced as company-reported preliminary leads. CAR-T is not interchangeable with neural stem cells, MSCs or HSCT. They were not independently appraised for this update and are not public conclusions.
- No new independently verified celebrity/public testimony selected. Testimony remains anecdotal.

## What changed and what did not

Add October 26 subsection immediately after the medical caution: transplant-complication prevention, supportive care, reporting standards, and the October 19 consumer-warning catch-up. Update review date and add the EMA manufacturing clarification/source in the existing Europe row. Retain original report and prior updates. Update sitemap lastmod for the article and add this source note with October 26 lastmod.

Health page, assets, stylesheet and price estimates remain unchanged: this is maintenance of an existing report, not a new report/link. No established/approved status is assigned to the investigational approaches. No medication instructions or clinic recommendations.

Local backups: _local-backups/stem-cells-2026-10-26/.
Remote backups: domains/managingexpectations.net/backups/stem-cells-20261026/.
DNS and HTTP checks confirmed Hostinger shared hosting at 195.35.15.247 (LiteSpeed/Hostinger). Deploy only article, note and sitemap to their directory-specific existing paths; no KillerWolf or DNS changes. Backup retrieval confirmed local article and sitemap matched live versions before editing.

Evidence folder: research/health/stem-cells-weekly-evidence-2026-10-26/ (local only). Contains official HTML/text/PDF snapshots, retrieval statuses, PubMed XML/records and registry JSON. Deployment/live validation recorded separately; this note is not itself a success assertion. No visual browser tool available: verify parsed HTML, relative links, live bytes, sitemap structure and asset availability.

Next review priorities: primary Japanese Stemirac decision, controlled follow-up of neural/iPSC therapies, long-term harms, exact product approvals and clinical-trial outcome changes rather than timestamps.

Medical boundary: education and source review only; not medical advice, diagnosis, dosing, treatment guidance, clinic endorsement or an instruction to travel.